Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-72 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6845 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
filingDate |
2014-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2022-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-102355308-B1 |
titleOfInvention |
Insulin-like growth factor 1 receptor-specific antibodies and uses thereof |
abstract |
The blood-brain barrier (BBB) prevents the transport of more than 500 Daltons of molecules from the blood to the brain. Receptor-mediated transcytoplasmic migration (RMT) promotes trans-BBB transport of specific molecules that bind to receptors on brain endothelial cells that form the BBB. Insulin-like growth factor 1 receptor (IGF1R)-binding antibodies or fragments thereof that traverse the BBB by RMT were identified. The antibody or fragment is used to deliver a load molecule across the BBB, where the load molecule may be a therapeutic agent or a detectable agent. The antibody is camelid VHH prepared by immunizing a llama with a 933-amino acid IGF1R polypeptide. A humanized form of the camelid VHH is also produced. |
priorityDate |
2014-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |